An open-label, flexible-dose, long-term safety and efficacy study of bifeprunox in the treatment of schizophrenia (extension of S154.3.001).
Phase of Trial: Phase III
Latest Information Update: 27 Apr 2010
At a glance
- Drugs Bifeprunox (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Laboratories
- 07 Sep 2007 Status changed from in progress to completed.
- 30 Sep 2006 New trial record.